Organon & Co.(OGN)
Pharmaceuticals
Specialty Pharma
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Holzbaur Lynette SVP and Corporate Controller | Sale | -26,448.366 | -100.00%0 | $13.35 | $353,080 | View SEC filing | |
| 2026-05-07 | Holzbaur Lynette SVP and Corporate Controller | Purchase | +26,448.366 | +100.17%52,850.793 | $13.35 | $353,080 | View SEC filing | |
| 2025-11-13 | COX CARRIE SMITH Executive Chair | Purchase | +65,400 | +524.50%77,869 | $7.67 | $501,755 | View SEC filing | |
| 2025-05-15 | COX CARRIE SMITH Director | Purchase | +12,469 | +100.00%12,469 | $8.07 | $100,591 | View SEC filing | |
| 2025-05-07 | Falcione Aaron Chief Human Resources Officer | Purchase | +5,500 | +9.57%62,973.661 | $8.77 | $48,235 | View SEC filing | |
| 2025-05-07 | Weaver Kirke Gen. Counsel & Corp. Secy. | Purchase | +8,045 | +18.10%52,489 | $9.21 | $74,054 | View SEC filing | |
| 2025-05-07 | Karp Daniel Executive VP, Corp. Dev. | Purchase | +3,500 | +8.11%46,669.46 | $8.24 | $28,828 | View SEC filing | |
| 2025-05-06 | WALSH MATTHEW M Chief Financial Officer | Purchase | +11,400 | +8.57%144,484 | $8.82 | $100,548 | View SEC filing | |
| 2025-05-06 | Ali Kevin Chief Executive Officer | Purchase | +34,000 | +13.67%282,731.157 | $8.80 | $299,370 | View SEC filing | |
| 2024-02-23 | Weaver Kirke Gen. Counsel & Corp. Secy. | Purchase | +2,720 | +21.83%15,181 | $18.36 | $49,939 | View SEC filing | |
| 2021-08-19 | Francisco Ma. Fatima Director | Purchase | +3,000 | +100.00%3,000 | $33.79 | $101,370 | View SEC filing |
1-11 of 11